GIA
CDLX icon

GHP Investment Advisors’s Cardlytics CDLX Stock Holding History

GHP Investment Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30
Closed -$16K – 937
2022
Q1 		$16K Buy
+30
New +$18.1K ﹤0.01% 638

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GHP Investment Advisors's CDLX Position: Q2 2022 in Review

GHP Investment Advisors sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 30 shares — an estimated $16K sold.

GHP Investment Advisors first reported a position in CDLX in Q1 2022 and held it in 1 quarter. The position peaked at $16K in Q1 2022. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.

  • GHP Investment Advisors reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
  • GHP Investment Advisors sold 30 Cardlytics shares in Q2 2022, an estimated $16K.
  • GHP Investment Advisors first reported a position in Cardlytics in Q1 2022 and held it in 1 quarter.
  • GHP Investment Advisors's Cardlytics position peaked at $16K in Q1 2022.
  • 138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.

Based on GHP Investment Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.